Targeting fundamentals of inflammation, autoimmunity and fibrosis

Granite Bio is a biotechnology company based in Basel, Switzerland, developing first-in-class antibodies. We are a diverse and passionate team of experts in immunology and inflammation. We take pride not only in what we achieve, but how we achieve it – driven by a shared sense of purpose of developing innovative and transformative therapies that improve patients’ lives. Our culture is inclusive and empowering and values openness and communication. We are a high-performing team who work hard together to make a meaningful and lasting impact. Granite is backed by leading healthcare venture firms including Versant Ventures, Novartis Venture Fund, Forbion and Sanofi Ventures.

  • TRANSFORM

    inflammatory, autoimmune and fibrotic diseases

  • DIFFERENTIATE

    by targeting emerging central disease biology nodes

  • IMPACT

    via selective depletion of pathogenic cells

Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology. Our pipeline is composed of two potential treatments:

GRT-001 depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. GRT-001 has completed a Phase 1a in healthy volunteers showing a positive safety profile and clear pharmacological activity. It is currently in Phase 1b testing in patients with inflammatory bowel disease.

GRT-002 blocks interleukin-3, a key player in autoimmune inflammation and type II inflammation, offering a new approach to treating itch and allergy. The molecule is in preclinical development and is expected to enter clinical trials in 2026.

  • Granite Bio - GRT-001

    GRT-001

    Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.

  • Granite Bio – GRT-002

    GRT-002

    Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.

Two first-in-class therapeutic antibodies GRT-001 and GRT-002

shape-rendering="geometricPrecision" text-rendering="geometricPrecision">

Pipeline:

Team:

Granite Bio Team:

Remembering:

Giorgio Ferrari
Associate Director Immunology

Giorgio's career in immunology was both distinguished and impactful. He started his career in Milan in the early 80's, at the Institute of Pharmacology Research ‘’Mario Negri’’, focusing on hematology and immunology in the laboratory of A. Mantovani.

Giorgio contributed significantly to the Immunology field during a decade at the renowned Basel Institute for Immunology, by unveiling key aspects of the immune response to microbial infection, particularly to mycobacteria and pursuing projects on antigen presentation and host-pathogen interaction. Giorgio co-authored multiple works which were published in high-impact factor journals, including "Cell". He later continued his work at the Biozentrum (University Basel) and subsequently at Actelion/Idorsia before joining Granite Bio in June of 2023 as Associate Director in Immunology, where he was a valued colleague and friend.

Beyond his professional achievements, Giorgio will be remembered as a devoted family man and a vibrant presence in the Basel scientific community through his passion, warmth, sociability and his joyful appreciation of life.

Board of Directors:

Scientific Advisors:

  • Vishwa Deep Dixit

    Yale University
    Innate Immunity

  • Christopher Denton

    University College London
    Fibrosis

  • Jörg Distler

    Düsseldorf University
    Fibrosis

  • Erica Herzog

    Yale University
    Pulmonary Fibrosis

  • Brian Feagan

    Ontario, Canada
    Inflammatory Bowel Disease

  • Florian Rieder

    Cleveland Clinic
    Inflammatory Bowel Disease

  • Scott Brian Snapper

    Boston/Harvard University
    Inflammatory Bowel Disease

  • Portrait Carrie Sokol

    Carrie Sokol

    Boston/Harvard University
    Type-II Inflammation

Open Positions: